# Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

> **NCT05039632** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Neoplasm in the Liver
- Metastatic Malignant Neoplasm in the Lung
- Metastatic Malignant Solid Neoplasm

## Interventions

- **OTHER:** Hafnium Oxide-containing Nanoparticles NBTXR3
- **RADIATION:** Radiation Therapy
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT05039632
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-08
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039632, "Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05039632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*